BALTIMORE, MD -- (Marketwired) -- 07/02/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandaí Biotechnology Inc. (OTCQB: PLPL) offer products that meet the unmet needs of athletes. These include immune system health and strength, maximization of blood flow during training, and aiding in post-workout recovery.
Professional and amateur athletes alike are constantly seeking an advantage to fight muscle fatigue and improve physical performance. This has spurred a growth in sports drinks and other 'nutraceutical' products as the athletic-minded consumer looks for an advantage via better performance. For example, in 2012, Global Industry Analysts (GIA) released a comprehensive report that forecast the consumption of sports and nutrition foods and drinks to be a $55 billion market in the U.S. alone by 2018.
Plandaí Biotechnology Inc.'s (OTCQB: PLPL) Phytofare Citrus Limonoid Glycoside Complex is a unique product that is primed to serve the unmet needs of these athletes. This offering utilizes the entire fruit including juice, pith, peel, and pulp from where all of the soluble phytonutrients are recovered. Plandaí has spent over a decade developing this botanical extract and has developed a product that delivers the related nutrients more effectively from an absorption perspective than any other comparable product.
In fact, the unique product contains all of vitamins A & C, bioflavonoids, (especially Hesperidin and Rutin), limonoids (especially limonin and nomilin), and numerous minerals, including potassium and pectin. There is extensive research showing that citrus bioflavonoids have tremendous anti-inflammatory properties. Moreover previous third-party testing has shown that athletes taking a high-dosage citrus limonoid complex have experienced faster post-work out recovery and the virtual elimination of muscle pulls.
The Company plans to conduct future studies and trials for this product and, once it receives approval and is introduced to the consumer, it will be marketed to include all of the major benefits including enhanced athletic performance. Clearly, Plandaí's next generation delivery system and high absorption advantages will give Plandai a superior edge over competitors and presents substantial revenue opportunities in a huge vertical market.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Goldman Small Cap Research
Most Popular Stories
- Obama, Ukraine Discuss Russian Incursion in Crimea
- Chinese May Have Spotted Malaysia Airlines Debris
- Social Media Causee Sleep Deprivation in Students
- First-time Jobless Claims Drop Unexpectedly
- Banks Buying Little From Minority Firms: Study
- General Electric Plans IPO of Credit Card Unit
- First-time U.S. Jobless Claims Hit 3-month Low
- U.S. Business Inventories Up, Retail Sales Down
- SXSW Crash Kills 2, Injures 23
- 'Candy Crush' Maker Files IPO